摘要
BACKGROUND Crohn's disease(CD)causes a range of digestive symptoms including recurrent diarrhea,abdominalgia,and flatulence,and severely impacts the quality of life of patients.Infliximab,a monoclonal antibody against tumor necrosis factor alpha,has recently been promoted as a therapeutic treatment for CD,but its safety margins remain uncertain.We report a case of rapidly progressive colorectal cancer that was diagnosed in a patient with CD who had previously been treated with infliximab.CASE SUMMARY This case report refers to a 40-year-old male with a 6-year history of CD.The patient underwent transverse colostomy because of inflammatory ileus in 2017.He subsequently received infliximab treatment in 2018.Ten months later,worsening contracture of the transverse colostomy was observed.Imaging tests indicated that the patient may have developed colon cancer with extensive peritoneal implantation.At the same time,colonoscopy revealed a rectal mass and pathological examination indicated well-differentiated adenocarcinoma.Palliative ileostomy was performed to improve defecation in 2019.During the operation,a small nodular mass in the mesentery of the small intestine was identified and pathological examination of the mass revealed advanced adenocarcinoma.The patient was diagnosed with advanced colorectal cancer and administered palliative chemotherapy.He died in June 2020.CONCLUSION We stress the importance of recognizing the possible occurrence of malignance in patients with CD receiving infliximab.
作者简介
Lin Xiao,0000-0001-8644-1568;Lie Sun,0000-0001-5609-530X;Kang Zhao,0000-0001-5253-6139;Corresponding author:Yi-Sheng Pan,MD,Doctor,Department of General Surgery,Peking University First Hospital,No.8 Xishiku Street,Beijing 100034,China.bdyypanyisheng@163.com,0000-0001-7256-5017.
